

March 11, 2019



MRI Interventions Reports 36% Increase in Fourth Quarter Revenue and Record Quarterly ClearPoint® Cases

Fourth Quarter Cash Burn from Operations Reduced to \$600,000

IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC) (the "Company") today announced financial results for its fourth fiscal quarter and full year ended December 31, 2018.

Fourth Quarter 2018 Highlights

- Increased fourth quarter revenue 36% year-over-year to a record \$2.3 million.
- Reported a record \$1.6 million in quarterly functional neurosurgery revenue, an increase of 21% over the prior year fourth quarter.
- Increased gross margin to 70%, compared with 61% in the prior year fourth quarter.
- Completed a record 188 procedures across the Company's product portfolio, an increase of 18% over the prior year fourth quarter.
- Secured five additional hospital evaluations of the ClearPoint platform.
- Achieved FDA clearance for the ClearPoint 2.0 software platform and the ClearPoint PURSUIT™ Neuro Aspiration System.
- Acquired a license to the CLS Tranberg® Therma Therapy System and laser applicators for use in neuro and spine, and commenced co-development efforts.
- Participated in the first patient cases in Voyager Therapeutics' Phase 2 VY-AADC Gene Therapy Trial for treatment of Parkinson's disease.
- Participated in the first patient dosing in Axovant Sciences' clinical study of AXO-Lenti-PD as a gene therapy for treatment of Parkinson's disease.
- Reduced cash used in operations to \$600,000, below the previous estimate of \$800,000.

Joe Burnett, President and Chief Executive Officer of MRI Interventions, Inc., said, "We produced a record fourth quarter including 36% growth in total revenue, a record 188 ClearPoint cases, a record \$1.6 million in functional neurosurgery revenue and a 70% gross margin while reducing cash used in operations to \$600,000. These results reflect diligent focus on our four-pillar growth strategy by our entire team and set the stage for an

even more exciting year ahead. This is reflected in our 2019 expectations, which call for 800 to 850 cases using our ClearPoint system and revenue of \$9.5 to \$10.5 million.

“In pillar one, functional neurosurgery, we again reported record case volumes and record revenue in the quarter. We also commenced evaluation at five new ClearPoint sites and increased the number of sites using our multiple procedures per day protocol to seven. The increase in case volume reflected resolution in late 2018 of the FDA actions that affected third-party providers in the laser ablation space and overall momentum for ClearPoint guided procedures. We also received FDA clearance in November for our ClearPoint 2.0 next-generation software platform and expect it will be available for purchase by all new and existing ClearPoint customers in the first half of 2019.

“In biologics and drug delivery, our second pillar, we are supporting multiple new gene therapy trials using a variety of combinations of our products and clinical support services. This includes commencement of services under our expanded agreement with Voyager as part of its Phase 2 and 3 VY-AADC clinical trial.

“In pillar three, therapy, we announced an agreement with CLS to co-develop hardware, disposables and software to make the ClearPoint platform work together with the FDA-cleared Tranberg Therma Therapy System in a single, coordinated and efficient workflow. We believe that adding laser therapy to our portfolio has the potential to turn our lowest revenue and margin procedure into our highest. We also received clearance for our ClearPoint PURSUIT Neuro Aspiration System designed in collaboration with the Mayo Clinic. The PURSUIT device allows surgeons to identify an aspiration target using real-time MRI guidance and monitor the aspiration during surgery of the ventricular system or cerebrum.

“And in pillar four, gaining global scale, we entered into a distribution agreement with CLS for the distribution in the U.S. and Canada of its laser ablation system for non-neuro applications.

“We believe these outcomes demonstrate the success of our efforts to transform our company into a full-line neuro and spine therapy company, with products and partnerships for navigation, laser ablation, deep-brain stimulation, aspiration, gene therapy and more. We are excited to continue these efforts in 2019 and expect noteworthy increases in both cases and revenue as we continue to advance our initiatives.”

2019 Outlook

The Company announced that it has raised its 2019 revenue expectation to be in a range of \$9.5 to \$10.5 million, representing year-over-year growth of 30% to 42%. The Company expects ClearPoint case volume to show similar growth in reaching an estimated range of 800 to 850 cases across its product portfolio.

Financial Results – Three Months Ended December 31, 2018

Functional neurosurgery revenue, which consists of disposable product sales and services related to cases utilizing the ClearPoint system, increased 21% to \$1.6 million for the three months ended December 31, 2018, from \$1.3 million for the same period in 2017. The increase was primarily due to an increase in ClearPoint case volume.

Biologics and drug delivery revenue, which include sales of disposable products and services related to customer-sponsored clinical trials and services, increased 1,029% to \$469,000 for the three months ended December 31, 2018, from \$42,000 for the same period in 2017.

Capital equipment and related service revenue, consisting of sales of ClearPoint reusable hardware and software and related services, decreased to \$174,000 for the three months ended December 31, 2018, from \$290,000 for the same period in 2017, due primarily to a decrease in sales of ClearPoint systems, which, as previously noted, historically have varied from quarter to quarter. The decrease in systems sales was partially offset by a 79% increase in capital equipment-related service revenues for the three months ended December 31, 2018 from the same period in 2017.

Gross margin for the three months ended December 31, 2018 improved to 70% from 61% in the same period in 2017, due primarily to favorable product mix of higher margin disposable products and services.

Research and development costs were \$481,000 for three months ended December 31, 2018, compared to \$582,000 for the same period in 2017, a decrease of 17%. Sales and marketing expenses were \$879,000 for the three months ended December 31, 2018, compared to \$1.0 million for the same period in 2017, a decrease of 13%. General and administrative expenses were \$1.2 million for the three months ended December 31, 2018, compared to \$1.3 million for the same period in 2017, a decrease of 4%.

Financial Results – Year Ended December 31, 2018

Functional neurosurgery revenue decreased 2% to \$5.4 million from \$5.5 million in 2017. The decrease was due primarily to two factors: (a) FDA actions taken in early 2018 that adversely affected third-party providers in the laser ablation space until resolutions were accepted by the FDA in the 2018 fourth quarter; and (b) a third-party provider introduced a new deep brain stimulation system that did not have approval for use in the MRI suite for most of 2018, which was resolved in the 2018 third quarter. In spite of these factors, cases continued to climb year-over-year, to 670 cases in 2018, compared with 629 in 2017.

Biologics and drug delivery revenue increased 177% to \$1.1 million for 2018, from \$405,000 in 2017. This increase was due primarily to the commencement of additional services during 2018, and to an increase in biologics and drug delivery product sales.

Capital equipment and related service revenue decreased to \$813,000 for 2018, from \$1.5 million in 2017, due primarily to a decrease in sales of ClearPoint systems, which, as previously noted, historically have varied from quarter to quarter. The decrease in systems sales was partially offset by a 12% increase in capital equipment-related service revenues for the year ended December 31, 2018, as compared to 2017.

Gross margin for the year ended December 31, 2018 improved to 67% from 61% in 2017. The increase was due primarily to increased contribution from higher margin disposables and services revenue.

Research and development costs were \$2.3 million in 2018, compared to \$2.8 million in

2017, a decrease of \$504,000, or 18%. Sales and marketing expenses were \$3.5 million for the year ended December 31, 2018, compared to \$4.0 million in 2017, a decrease of \$424,000, or 11%. General and administrative expenses were \$4.3 million for 2018, compared to \$4.0 million for in 2017, an increase of \$279,000, or 7%.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2018 fourth quarter and full year financial results today at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) that may be accessed by visiting the Company's website at www.mriinterventions.com and selecting "Investors" / "News" / "IR Calendar." Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until March 25, 2019 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's website at www.mriinterventions.com, on the "Investor Relations" page.

About MRI Interventions, Inc.

Building on the imaging power of magnetic resonance imaging ("MRI"), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.

Forward-Looking Statements

Statements herein concerning MRI Interventions, Inc.'s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's ability to obtain additional financing; estimates regarding the sufficiency of the Company's cash resources; future revenues from sales of the company's ClearPoint Neuro Navigation System products; and the company's ability to market, commercialize and achieve broader market acceptance for the company's ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the company's actual results are described in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2017, and the Company's Quarterly Report for the quarter ended September 20, 2018, both of which have been filed with the Securities and Exchange Commission, and the Company's Annual Report on Form 10-K for the year ended December 31, 2018, which the company intends to file with the Securities and Exchange Commission on or about April 1, 2019.

Contact:

Harold A. Hurwitz, Chief Financial Officer
(949) 900-6833

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

MRI INTERVENTIONS, INC.**Consolidated Statements of Operations**

	Three Months Ended December 31,	
	2018	2017
Revenues:		
Product revenues	\$ 1,994,019	\$ 1,580,723
Service and other revenues	282,504	98,655
Total revenues	<u>2,276,523</u>	<u>1,679,378</u>
Cost of revenues	689,088	659,000
Research and development costs	481,293	582,158
Sales and marketing expenses	878,997	1,011,193
General and administrative expenses	<u>1,206,169</u>	<u>1,259,848</u>
Operating loss	(979,024)	(1,832,821)
Other income (expense):		
Gain (loss) on change in fair value of derivative liabilities	-	(23,336)
Other income (loss), net	(920)	10,130
Interest expense, net	<u>(237,996)</u>	<u>(235,656)</u>
Net loss	<u>\$ (1,217,940)</u>	<u>\$ (2,081,683)</u>
Net loss per share attributable to common stockholders:		
Basic and diluted	<u>\$ (0.11)</u>	<u>\$ (0.20)</u>
Weighted average shares outstanding:		
Basic and diluted	<u>11,012,208</u>	<u>10,571,422</u>

MRI INTERVENTIONS, INC.**Consolidated Statements of Operations**

	Years Ended December 31,	
	2018	2017
Revenues:		
Product revenues	\$ 6,685,020	\$ 7,024,010

Service and other revenues	668,246	355,515
Total revenues	<u>7,353,266</u>	<u>7,379,525</u>
Cost of revenues	2,433,069	2,898,808
Research and development costs	2,310,139	2,813,733
Sales and marketing expenses	3,532,040	3,956,455
General and administrative expenses	<u>4,325,786</u>	<u>4,046,366</u>
Operating loss	(5,247,768)	(6,335,837)
Other income (expense):		
Gain on change in fair value of derivative liabilities	64,318	24,728
Other income, net	364	16,682
Interest expense, net	<u>(980,383)</u>	<u>(872,926)</u>
Net loss	<u>\$ (6,163,469)</u>	<u>\$ (7,167,353)</u>
Net loss per share attributable to common stockholders:		
Basic and diluted	<u>\$ (0.56)</u>	<u>\$ (0.93)</u>
Weighted average shares outstanding:		
Basic and diluted	<u>10,928,213</u>	<u>7,738,343</u>

MRI INTERVENTIONS, INC.

Consolidated Balance Sheets

	<u>December 31,</u>	
	<u>2018</u>	<u>2017</u>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 3,101,133	\$ 9,289,831
Accounts receivable, net	1,233,896	949,415
Inventory, net	2,105,976	2,314,184
Prepaid expenses and other current assets	<u>213,684</u>	<u>192,727</u>
Total current assets	6,654,689	12,746,157
Property and equipment, net	377,706	267,667
Software license inventory	801,900	871,900
Other assets	22,538	11,641
Total assets	<u>\$ 7,856,833</u>	<u>\$ 13,897,365</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 500,929	\$ 759,445
Accrued compensation	764,960	806,445
Other accrued liabilities	390,838	480,159
Derivative liabilities	-	95,786
Deferred product and service revenues	350,963	256,178
Senior secured note payable	-	2,000,000
Total current liabilities	<u>2,007,690</u>	<u>4,398,013</u>

Accrued interest	857,500	752,500
2010 junior secured notes payable, net of unamortized discount of \$1,459,209 and \$1,956,458 at December 31, 2018 and 2017, respectively	1,540,791	1,043,542
2014 junior secured notes payable, net of unamortized discount and deferred issuance costs aggregating \$35,149 and \$100,430 at December 31, 2018 and 2017, respectively	1,939,850	1,874,570
Total liabilities	<u>6,345,831</u>	<u>8,068,625</u>
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$0.01 par value; 25,000,000 shares authorized at December 31, 2018 and 2017; none issued and outstanding at December 31, 2018 and 2017	-	-
Common stock, \$0.01 par value; 200,000,000 shares authorized at December 31, 2018 and 2017; 11,018,364 and 10,693,851 shares issued and outstanding at December 31, 2018 and 2017, respectively	110,183	106,937
Additional paid-in capital	108,600,405	106,757,920
Accumulated deficit	(107,199,586)	(101,036,117)
Total stockholders' equity	<u>1,511,002</u>	<u>5,828,740</u>
Total liabilities and stockholders' equity	<u>\$ 7,856,833</u>	<u>\$ 13,897,365</u>

MRI INTERVENTIONS, INC.

Consolidated Statements of Cash Flows

	<u>Years Ended December 31,</u>	
	<u>2018</u>	<u>2017</u>
Cash flows from operating activities:		
Net loss	\$ (6,163,469)	\$ (7,167,353)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Depreciation and amortization	109,439	116,454
Share-based compensation	1,231,379	1,245,601
Expenses paid through the issuance of common stock	77,500	502,032
Gain on change in fair value of derivative liabilities	(64,318)	(24,178)
Amortization of debt issuance costs and original issue discounts	562,529	426,358
Increase (decrease) in cash resulting from changes in:		
Accounts receivable	(284,481)	(83,472)
Inventory	122,220	(469,922)
Prepaid expenses and other current assets	(20,957)	(57,731)
Other assets	(10,897)	(999)

Accounts payable and accrued expenses	(284,322)	(512,362)
Deferred revenue	94,785	33,061
Net cash flows from operating activities	<u>(4,630,592)</u>	<u>(5,992,511)</u>
Cash flows from investing activities:		
Purchases of property and equipment	<u>(63,490)</u>	<u>(26,752)</u>
Net cash flows from investing activities	<u>(63,490)</u>	<u>(26,752)</u>
Cash flows from financing activities:		
Net proceeds from equity private placements and exercise of warrants	-	11,993,320
Exercise of warrants	505,384	-
Repayment of senior secured note	<u>(2,000,000)</u>	<u>-</u>
Net cash flows from financing activities	<u>(1,494,616)</u>	<u>11,993,320</u>
Net change in cash and cash equivalents	(6,188,698)	5,974,057
Cash and cash equivalents, beginning of year	9,289,831	3,315,774
Cash and cash equivalents, end of year	<u>\$ 3,101,133</u>	<u>\$ 9,289,831</u>

SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid for:

Income taxes	\$ -	\$ -
Interest	<u>\$ 210,722</u>	<u>\$ 348,528</u>



Source: MRI Interventions, Inc.